The immunotherapy drug, durvalumab, has been the standard of care for patients with stage III non-small cell lung cancer(NSCLC) to improve survival, when prescribed after chemotherapy and radiation therapy.
Reviewed by Danielle Ellis, B.Sc.Sep 11 2023 But patients with an epidermal growth factor receptor gene mutation have not seen the same survival benefit.
Researchers analyzed data from 22 medical institutions, where patients with stage III NSCLC were treated between 2015 and 2022. Out of the 89 patients with the EGFR genetic mutation, those who received chemoradiation followed by EGFR TKI therapy lived longer, compared to those who received durvalumab after chemoradiation, or patients who had no additional treatment.
Vi har opsummeret denne nyhed, så du kan læse den hurtigt. Hvis du er interesseret i nyheden, kan du læse hele teksten her. Læs mere: